Clinical and Molecular Aspects of Vitiligo Treatments
Abstract
:1. Introduction
2. Stabilization Treatments
3. Repigmenting Treatments
4. Stabilizing and Repigmenting Treatments
Conflicts of Interest
References
- Ezzedine, K.; Eleftheriadou, V.; Whitton, M.; Van Geel, N. Vitiligo. Lancet 2015, 386, 74–84. [Google Scholar] [CrossRef]
- Picardo, M.; Dell’Anna, M.L.; Ezzedine, K.; Hamzavi, I.; Harris, J.E.; Parsad, D.; Taieb, A. Vitiligo. Nat. Rev. Dis. Prim. 2015. [Google Scholar] [CrossRef] [PubMed]
- Ezzedine, K.; Lim, H.W.; Suzuki, T.; Katayama, I.; Hamzavi, I.; Lan, C.C.; Goh, B.K.; Anbar, T.; de Castro, C.S.; Lee, A.Y.; et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012, 25. [Google Scholar] [CrossRef] [PubMed]
- Passeron, T. Medical and Maintenance Treatments for Vitiligo. Dermatol. Clin. 2017, 35, 163–170. [Google Scholar] [CrossRef] [PubMed]
- Boniface, K.; Seneschal, J.; Picardo, M.; Taïeb, A. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clin. Rev. Allergy Immunol. 2018, 54, 52–67. [Google Scholar] [CrossRef] [PubMed]
- Esmat, S.; Hegazy, R.A.; Shalaby, S.; Chu-Sung Hu, S.; Lan, C.C.E. Phototherapy and Combination Therapies for Vitiligo. Dermatol. Clin. 2017, 35, 171–192. [Google Scholar] [CrossRef] [PubMed]
- Benzekri, L.; Gauthier, Y. Clinical markers of vitiligo activity. J. Am. Acad. Dermatol. 2017, 76, 856–862. [Google Scholar] [CrossRef] [PubMed]
- Pasricha, J.S.; Khaitan, B.K. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int. J. Dermatol. 1993, 32, 753–757. [Google Scholar] [CrossRef] [PubMed]
- Kanwar, A.J.; Mahajan, R.; Parsad, D. Low-Dose Oral Mini-Pulse Dexamethasone Therapy in Progressive Unstable Vitiligo. J. Cutan. Med. Surg. 2013, 17, 259–268. [Google Scholar] [CrossRef] [PubMed]
- Radakovic-Fijan, S.; Fürnsinn-Friedl, A.M.; Hönigsmann, H.; Tanew, A. Oral dexamethasone pulse treatment for vitiligo. J. Am. Acad. Dermatol. 2001, 44, 814–817. [Google Scholar] [CrossRef] [PubMed]
- Spritz, R.A. Shared Genetic Relationships Underlying Generalized Vitiligo and Autoimmune Thyroid Disease. Thyroid 2010, 20, 745–754. [Google Scholar] [CrossRef] [PubMed]
- Van Geel, N.A.C.; Mollet, I.G.; De Schepper, S.; Tjin, E.P.; Vermaelen, K.; Clark, R.A.; Kupper, T.S.; Luiten, R.M.; Lambert, J. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010, 23, 375–384. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.; Birlea, S.A.; Fain, P.R.; Gowan, K.; Riccardi, S.L.; Holland, P.J.; Bennett, D.C.; Herbstman, D.M.; Wallace, M.R.; McCormack, W.T.; et al. Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J. Investig. Dermatol. 2011, 131, 1308–1312. [Google Scholar] [CrossRef] [PubMed]
- Spritz, R.A. Recent progress in the genetics of generalized vitiligo. J. Genet. Genom. 2011, 38, 271–278. [Google Scholar] [CrossRef] [PubMed]
- Spritz, R.A.; Andersen, G.H.L. Genetics of Vitiligo. Dermatol. Clin. 2017, 35, 245–255. [Google Scholar] [CrossRef] [PubMed]
- Czajkowski, R.; Mecińska-Jundziłł, K. Current aspects of vitiligo genetics. Postepy Dermatol. Alergol. 2014, 31, 247–255. [Google Scholar] [CrossRef] [PubMed]
- Kemp, E.H.; Gavalas, N.G.; Gawkrodger, D.J.; Weetman, A.P. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun. Rev. 2007, 6, 138–142. [Google Scholar] [CrossRef] [PubMed]
- Boissy, R.E.; Spritz, R.A. Frontiers and controversies in the pathobiology of vitiligo: Separating the wheat from the chaff. Exp. Dermatol. 2009, 18, 583–585. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.X.; Wang, Q.Q.; Wu, J.Q.; Jiang, M.; Chen, L.; Zhang, C.F.; Xiang, L.H. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol. 2016, 174, 1318–1326. [Google Scholar] [CrossRef] [PubMed]
- Ogg, B.G.S.; Dunbar, P.R.; Romero, P.; Chen, J.L.; Cerundolo, V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. Analysis 1998, 188, 1203–1208. [Google Scholar] [CrossRef]
- Harris, J.E.; Harris, T.H.; Weninger, W.; Wherry, E.J.; Hunter, C.A.; Turka, L.A. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8 + T-cell accumulation in the skin. J. Investig. Dermatol. 2012, 132, 1869–1876. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luiten, R.M.; Van Den Boorn, J.G.; Konijnenberg, D.; Dellemijn, T.A.; van der Veen, J.P.; Bos, J.D.; Melief, C.J.; Vyth-Dreese, F.A. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Investig. Dermatol. 2009, 129, 2220–2232. [Google Scholar] [CrossRef]
- Lee, A.Y. Role of keratinocytes in the development of vitiligo. Ann. Dermatol. 2012, 24, 115–125. [Google Scholar] [CrossRef] [PubMed]
- Rashighi, M.; Agarwal, P.; Richmond, J.M.; Harris, T.H.; Dresser, K.; Su, M.W.; Zhou, Y.; Deng, A.; Hunter, C.A.; Luster, A.D.; et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 2014, 6. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Zhou, M.; Lin, F.; Liu, D.; Hong, W.; Lu, L.; Zhu, Y.; Xu, A. Interferon-γ induces senescence in normal human melanocytes. PLoS ONE 2014, 9. [Google Scholar] [CrossRef] [PubMed]
- Craiglow, B.G.; King, B.A. Tofacitinib citrate for the treatment of Vitiligo a pathogenesis-directed therapy. JAMA Dermatol. 2015, 151, 1110–1112. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.Y.; Strassner, J.P.; Refat, M.A.; Harris, J.E.; King, B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J. Am. Acad. Dermatol. 2017, 77, 675–682. [Google Scholar] [CrossRef] [PubMed]
- Iannella, G.; Greco, A.; Didona, D.; Didona, B.; Granata, G.; Manno, A.; Pasquariello, B.; Magliulo, G. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun. Rev. 2016, 15, 335–343. [Google Scholar] [CrossRef] [PubMed]
- Singh, H.; Kumaran, M.S.; Bains, A.; Parsad, D. A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology 2015, 231, 286–290. [Google Scholar] [CrossRef] [PubMed]
- Radmanesh, M.; Saedi, K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J. Dermatol. Treat. 2006, 17, 151–153. [Google Scholar] [CrossRef] [PubMed]
- Khurrum, H.; AlGhamdi, K.M.; Osman, E. Screening of glaucoma or cataract prevalence in vitiligo patients and its relationship with periorbital steroid use. J. Cutan. Med. Surg. 2016, 20, 146–149. [Google Scholar] [CrossRef] [PubMed]
- Moretti, S.; Fabbri, P.; Baroni, G.; Berti, S.; Bani, D.; Berti, E.; Nassini, R.; Lotti, T.; Massi, D. Keratinocyte dysfunction in vitiligo epidermis: Cytokine microenvironment and correlation to keratinocyte apoptosis. Histol. Histopathol. 2009, 24, 849–857. [Google Scholar] [CrossRef] [PubMed]
- Taïeb, A. Vitiligo as an inflammatory skin disorder: A therapeutic perspective. Pigment Cell Melanoma Res. 2012, 25, 9–13. [Google Scholar] [CrossRef] [PubMed]
- Sravani, P.V.; Babu, N.K.; Gopal, K.V.; Rao, G.R.; Rao, A.R.; Moorthy, B.; Rao, T.R. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J. Dermatol. Venereol. Leprol. 2009, 75, 268. [Google Scholar] [CrossRef] [PubMed]
- Wagner, R.Y.; Luciani, F.; Cario-André, M.; Rubod, A.; Petit, V.; Benzekri, L.; Ezzedine, K.; Lepreux, S.; Steingrimsson, E.; Taieb, A.; et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J. Investig. Dermatol. 2015, 135, 1810–1819. [Google Scholar] [CrossRef] [PubMed]
- Tang, A.; Eller, M.S.; Hara, M.; Yaar, M.; Hirohashi, S.; Gilchrest, B.A. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J. Cell Sci. 1994, 107, 983–992. [Google Scholar] [PubMed]
- Levy, C.; Khaled, M. Ecad vitiliGONE. Pigment Cell Melanoma Res. 2015, 28, 376–377. [Google Scholar] [CrossRef] [PubMed]
- Picardo, M.; Bastonini, E. A new view of vitiligo: Looking at normal-appearing skin. J. Investig. Dermatol. 2015, 135, 1713–1714. [Google Scholar] [CrossRef] [PubMed]
- Cario-André, M.; Pain, C.; Gauthier, Y.; Taïeb, A. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. Pigment Cell Res. 2007, 20, 385–393. [Google Scholar] [CrossRef] [PubMed]
- Gauthier, Y.; Cario-Andre, M.; Lepreux, S.; Pain, C.; Taïeb, A. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br. J. Dermatol. 2003, 148, 95–101. [Google Scholar] [CrossRef] [PubMed]
- Reichert Faria, A.; Jung, J.E.; Silva de Castro, C.C.; de Noronha, L. Reduced immunohistochemical expression of adhesion molecules in vitiligo skin biopsies. Pathol. Res. Pract. 2017, 213, 199–204. [Google Scholar] [CrossRef] [PubMed]
- Laddha, N.C.; Dwivedi, M.; Mansuri, M.S.; Gani, A.R.; Ansarullah, M.; Ramachandran, A.V.; Dalai, S.; Begum, R. Vitiligo: Interplay between oxidative stress and immune system. Exp. Dermatol. 2013, 22, 245–250. [Google Scholar] [CrossRef] [PubMed]
- Khan, R.; Satyam, A.; Gupta, S.; Sharma, V.K.; Sharma, A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch. Dermatol. Res. 2009, 301, 731–737. [Google Scholar] [CrossRef] [PubMed]
- Zailaie, M.Z. Epidermal hydrogen peroxide is not increased in lesional and non-lesional skin of vitiligo. Arch. Dermatol. Res. 2017, 309, 31–42. [Google Scholar] [CrossRef] [PubMed]
- Shi, M.H.; Wu, Y.; Li, L.; Cai, Y.F.; Liu, M.; Gao, X.H.; Chen, H.D. Meta-analysis of the association between vitiligo and the level of superoxide dismutase or malondialdehyde. Clin. Exp. Dermatol. 2017, 42, 21–29. [Google Scholar] [CrossRef] [PubMed]
- Xiao, B.H.; Shi, M.; Chen, H.; Cui, S.; Wu, Y.; Gao, X.H.; Chen, H.D. Glutathione Peroxidase Level in Patients with Vitiligo: A Meta-Analysis. Biomed. Res. Int. 2016. [Google Scholar] [CrossRef] [PubMed]
- Yildirim, M.; Baysal, V.; Inaloz, H.S.; Can, M. The role of oxidants and antioxidants in generalized vitiligo at tissue level. J. Eur. Acad. Dermatol. Venereol. 2004, 18, 683–686. [Google Scholar] [CrossRef] [PubMed]
- Xie, H.; Zhou, F.; Liu, L.; Zhu, G.; Li, Q.; Li, C.; Gao, T. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J. Dermatol. Sci. 2016, 81, 3–9. [Google Scholar] [CrossRef] [PubMed]
- Jian, Z.; Li, K.; Song, P.; Zhu, G.; Zhu, L.; Cui, T.; Liu, B.; Tang, L.; Wang, X.; Wang, G.; et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: A possible mechanism for melanocyte degeneration in vitiligo. J. Investig. Dermatol. 2014, 134, 2221–2230. [Google Scholar] [CrossRef] [PubMed]
- Tobin, D.J.; Swanson, N.N.; Pittelkow, M.R.; Peters, E.M.; Schallreuter, K.U. Melanocytes are not absent in lesional skin of long duration vitiligo. J. Pathol. 2000, 191, 407–416. [Google Scholar] [CrossRef]
- Richmond, J.M.; Frisoli, M.L.; Harris, J.E. Innate immune mechanisms in vitiligo: Danger from within. Curr. Opin. Immunol. 2013, 25, 676–682. [Google Scholar] [CrossRef] [PubMed]
- Dell’Anna, M.L.; Mastrofrancesco, A.; Sala, R.; Venturini, M.; Ottaviani, M.; Vidolin, A.P.; Leone, G.; Calzavara, P.G.; Westerhof, W.; Picardo, M. Antioxidants and narrow band-UVB in the treatment of vitiligo: A double-blind placebo controlled trial. Clin. Exp. Dermatol. 2007, 32, 631–636. [Google Scholar] [CrossRef] [PubMed]
- Middelkamp-Hup, M.A.; Bos, J.D.; Rius-diaz, F.; Gonzalez, S.; Westerhof, W. Treatment of vitiligo vulgaris with narrow-band UVB and oral polypodium leucotomos extract: A randomized double-blind placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 942–950. [Google Scholar] [CrossRef] [PubMed]
- Parsad, D.; Pandhi, R.; Juneja, A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin. Exp. Dermatol. 2003, 28, 285–287. [Google Scholar] [CrossRef] [PubMed]
- Kanwar, A.; Parsad, D.; Mahajan, R.; Singh, A. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J. Dermatol. Venereol. Leprol. 2014, 80, 29. [Google Scholar] [CrossRef] [PubMed]
- Song, X.; Xu, A.; Pan, W.; Wallin, B.; Kivlin, R.; Lu, S.; Cao, C.; Bi, Z.; Wan, Y. Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int. J. Mol. Med. 2008, 22, 9–16. [Google Scholar] [PubMed]
- Rodrigues, M.; Ezzedine, K.; Hamzavi, I.; Pandya, A.G.; Harris, J.E. New discoveries in the pathogenesis and classification of vitiligo. J. Am. Acad. Dermatol. 2017, 77, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Bhardwaj, S.; Rani, S.; Srivastava, N.; Kumar, R.; Parsad, D. Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo. Cytokine 2017, 91, 153–161. [Google Scholar] [CrossRef] [PubMed]
- Boniface, K.; Jacquemin, C.; Darrigade, A.S.; Dessarthe, B.; Martins, C.; Boukhedouni, N.; Vernisse, C.; Grasseau, A.; Thiolat, D.; Rambert, J.; et al. Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. J. Investig. Dermatol. 2018, 138, 355–364. [Google Scholar] [CrossRef] [PubMed]
- Kumar, R.; Parsad, D.; Kanwar, A.; Kaul, D. Altered levels of LXR-α: Crucial implications in the pathogenesis of vitiligo. Exp. Dermatol. 2012, 21, 853–858. [Google Scholar] [CrossRef] [PubMed]
- Le Poole, I.C.; van den Wijngaard, R.M.; Westerhof, W.; Das, P.K. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br. J. Dermatol. 1997, 137, 171–178. [Google Scholar] [CrossRef] [PubMed]
- Esmat, S.M.; El-Tawdy, A.M.; Hafez, G.A.; Zeid, O.A.; Abdel Halim, D.M.; Saleh, M.A.; Leheta, T.M.; Elmofty, M. Acral lesions of vitiligo: Why are they resistant to photochemotherapy? J. Eur. Acad. Dermatol. Venereol. 2012, 26, 1097–1104. [Google Scholar] [CrossRef] [PubMed]
- Rani, S.; Chauhan, R.; Parsad, D.; Kumar, R. Effect of Dickkopf1 on the senescence of melanocytes: In vitro study. Arch. Dermatol. Res. 2018, 310, 343–350. [Google Scholar] [CrossRef] [PubMed]
- Rani, S.; Bhardwaj, S.; Srivastava, N.; Sharma, V.L.; Parsad, D.; Kumar, R. Senescence in the lesional fibroblasts of non-segmental vitiligo patients. Arch. Dermatol. Res. 2017, 309, 123–132. [Google Scholar] [CrossRef] [PubMed]
- Kovacs, D.; Bastonini, E.; Ottaviani, M.; Cota, C.; Migliano, E.; Dell’Anna, M.L.; Picardo, M. Vitiligo Skin: Exploring the Dermal Compartment. J. Investig. Dermatol. 2018, 138, 394–404. [Google Scholar] [CrossRef] [PubMed]
- Gan, E.Y.; Eleftheriadou, V.; Esmat, S.; Hamzavi, I.; Passeron, T.; Böhm, M.; Anbar, T.; Goh, B.K.; Lan, C.E.; Lui, H.; et al. Repigmentation in vitiligo: Position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2017, 30, 28–40. [Google Scholar] [CrossRef] [PubMed]
- Bishnoi, A.; Parsad, D. Commentary on effect of procedural-related variables on melanocyte-keratinocyte suspension transplantation in nonsegmental stable vitiligo. Dermatol. Surg. 2017, 43, 236–237. [Google Scholar] [CrossRef] [PubMed]
- Falabella, R.; Barona, M.I. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009, 22, 42–65. [Google Scholar] [CrossRef] [PubMed]
- Bishnoi, A.; Parsad, D. Repigmentation patterns in vitiligo: Where do we stand? Br. J. Dermatol. 2016, 175, 460–461. [Google Scholar] [CrossRef] [PubMed]
- Kumar, R.; Parsad, D.; Kanwar, A.J.; Kaul, D. Altered levels of Ets-1 transcription factor and matrix metalloproteinases in melanocytes from patients with vitiligo. Br. J. Dermatol. 2011, 165, 285–291. [Google Scholar] [CrossRef] [PubMed]
- El Mofty, M.; Esmat, S.; Hunter, N.; Mashaly, H.M.; Dorgham, D.; Shaker, O.; Ibrahim, S. Effect of different types of therapeutic trauma on vitiligo lesions. Dermatol. Ther. 2017, 30. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.S.; Lan, C.C.E.; Chiou, M.H.; Yu, H.S. Basic fibroblast growth factor promotes melanocyte migration via increased expression of p125FAK on melanocytes. Acta. Derm. Venereol. 2006, 86, 498–502. [Google Scholar] [CrossRef] [PubMed]
- Choi, Y.M.; Diehl, J.; Levins, P.C. Promising alternative clinical uses of prostaglandin F2α analogs: Beyond the eyelashes. J. Am. Acad. Dermatol. 2015, 72, 712–716. [Google Scholar] [CrossRef] [PubMed]
- Anbar, T.S.; El-Ammawi, T.S.; Abdel-Rahman, A.T.; Hanna, M.R. The effect of latanoprost on vitiligo: A preliminary comparative study. Int. J. Dermatol. 2015, 54, 587–593. [Google Scholar] [CrossRef] [PubMed]
- Parsad, D.; Pandhi, R.; Dogra, S.; Kumar, B. Topical prostaglandin analog (PGE2) in vitiligo—A preliminary study. Int. J. Dermatol. 2002, 41, 942–945. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Parsad, D.; Bhattacharjee, R.; Muthu, S.K. A prospective right-left comparative study to evaluate the efficacy and tolerability of combination of NB-UVB and topical bimatoprost 0.03% eye drops versus NB-UVB given alone in patients of vitiligo vulgaris. J. Eur. Acad. Dermatol. Venereol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Regazzetti, C.; Joly, F.; Marty, C.; Rivier, M.; Mehul, B.; Reiniche, P.; Mounier, C.; Rival, Y.; Piwnica, D.; Cavalié, M.; et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: A promising target for repigmenting vitiligo patients. J. Investig. Dermatol. 2015, 135, 3105–3114. [Google Scholar] [CrossRef] [PubMed]
- Birlea, S.A.; Costin, G.E.; Roop, D.R.; Norris, D.A. Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization. Med. Res. Rev. 2017, 37, 907–935. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.Y.; Jeon, S.Y.; Hong, J.W.; Choi, K.W.; Lee, C.Y.; Choi, S.J.; Kim, J.H.; Song, K.H.; Kim, K.H. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: A proposed action mechanism for combination. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 609–616. [Google Scholar] [CrossRef] [PubMed]
- Akdeniz, N.; Yavuz, I.H.; Gunes Bilgili, S.; Ozaydin Yavuz, G.; Calka, O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasoneand calcipotriol in vitiligo. J. Dermatol. Treat. 2014, 25, 196–199. [Google Scholar] [CrossRef] [PubMed]
- Bhatnagar, A.; Kanwar, A.J.; Parsad, D.; De, D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: An open prospective study. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 638–642. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.; Chu, H.; Lee, H.; Kim, M.; Kim, D.S.; Oh, S.H. A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo. Dermatology 2016, 232, 224–229. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Qiao, M.; Wang, X.; Zhao, X.; Sun, Q. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: A meta-analysis. Photodermatol. Photoimmunol. Photomed. 2017, 33, 22–31. [Google Scholar] [CrossRef] [PubMed]
- Bhatnagar, A.; Kanwar, A.J.; Parsad, D.; De, D. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: An open prospective comparative study. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 1381–1385. [Google Scholar] [CrossRef] [PubMed]
- El Mofty, M.; Essmat, S.; Youssef, R.; Sobeih, S.; Mahgoub, D.; Ossama, S.; Saad, A.; El Tawdy, A.; Mashaly, H.M.; Saney, I.; et al. The role of systemic steroids and phototherapy in the treatment of stable vitiligo: A randomized controlled trial. Dermatol. Ther. 2016, 29, 406–412. [Google Scholar] [CrossRef] [PubMed]
- Kanwar, A.J.; Dogra, S.; Parsad, D.; Kumar, B. Narrow-band UVB for the treatment of vitiligo: An emerging effective and well-tolerated therapy. Int. J. Dermatol. 2005, 44, 57–60. [Google Scholar] [CrossRef] [PubMed]
- Moftah, N.H.; El-Barbary, R.A.H.; Ismail, M.A.; Ali, N.A.M. Effect of narrow band-ultraviolet B on CD4+CD25highFoxP3+T-lymphocytes in the peripheral blood of vitiligo patients. Photodermatol. Photoimmunol. Photomed. 2014, 30, 254–261. [Google Scholar] [CrossRef] [PubMed]
- Choi, C.P.; Kim, Y.I.; Lee, J.W.; Lee, M.H. The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase-1, transforming growth factor-beta1 and type I collagen in human skin fibroblasts. Clin. Exp. Dermatol. 2007, 32, 180–185. [Google Scholar] [CrossRef] [PubMed]
- Lan, C.C.E.; Wu, C.S.; Chen, G.S.; Yu, H.S. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: New insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. Br. J. Dermatol. 2011, 164, 490–496. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bishnoi, A.; Parsad, D. Clinical and Molecular Aspects of Vitiligo Treatments. Int. J. Mol. Sci. 2018, 19, 1509. https://doi.org/10.3390/ijms19051509
Bishnoi A, Parsad D. Clinical and Molecular Aspects of Vitiligo Treatments. International Journal of Molecular Sciences. 2018; 19(5):1509. https://doi.org/10.3390/ijms19051509
Chicago/Turabian StyleBishnoi, Anuradha, and Davinder Parsad. 2018. "Clinical and Molecular Aspects of Vitiligo Treatments" International Journal of Molecular Sciences 19, no. 5: 1509. https://doi.org/10.3390/ijms19051509